Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 20 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 7 concluded trials, 14% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 1, 2026 | Descartes-08 for Patients With Systemic Lupus Erythematosus | Trial Milestone | Phase 2 |
| December 30, 2026 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Trial Milestone | Phase 3 |
| November 15, 2027 | Descartes-08 in Autoantibody Myositis | Trial Milestone | Phase 2 |
| December 15, 2027 | Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders | Trial Milestone | Phase 1/Phase 2 |
Track RNAC alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RNAC in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.